Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1544452 | 0.84 | ALDH1A1 (0.43) | HSD11B1KMT2ATSHRALDH1A1 | |
| SCHEMBL9768640 | 0.83 | HSD11B1 (0.50) | HSD11B1PTGS2ALDH1A1PTGS1 | |
| SCHEMBL1544768 | 0.83 | PTGS2 (0.47) | HSD11B1PTGS2KMT2AALDH1A1PTGS1 | |
| SCHEMBL9220455 | 0.83 | HSD11B1 (0.50) | HSD11B1DRD2KMT2ATSHRALDH1A1 | |
| SCHEMBL4172936 | 0.83 | HSD11B1 (0.43) | HSD11B1PTGS2ALDH1A1 | |
| SCHEMBL1544862 | 0.82 | PTGS2 (0.51) | PTGS2KMT2ATSHRALDH1A1PTGS1 | |
| SCHEMBL822698 | 0.78 | HSD11B1 (0.68) | HSD11B1DRD2KMT2ATSHRALDH1A1 | |
| SCHEMBL11527657 | 0.78 | HSD11B1 (0.43) | HSD11B1PTGS2ALDH1A1 | |
| SCHEMBL1999427 | 0.77 | HSD11B1 (0.35) | HSD11B1PTGS2KMT2ATSHRALDH1A1 | |
| SCHEMBL9224690 | 0.77 | HSD11B1 (0.50) | HSD11B1PTGS2ALDH1A1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0495226-B1 | 3-Aryl-5-alkylthio-4H-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma | MERRELL DOW PHARMA (US) | 1995-10-11 | — | — | EP | claimed |
| US-5260450-A | Anticonvulsants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-11-09 | — | — | US | claimed |
| EP-0276793-B1 | 3-ARYL-5-ALKYLTHIO-4H-1,2,4-TRIAZOLES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-06-16 | — | — | EP | claimed |
| US-5158968-A | 3-aryl-5-alkylthio-4H-1,2,4-traizoles for treatment of hyperreflexia due to spinal trauma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-10-27 | — | — | US | claimed |
| US-5143933-A | Anticonvulsants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-09-01 | — | — | US | claimed |
| EP-0495226-A2 | 3-Aryl-5-alkylthio-4H-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-22 | — | — | EP | claimed |
| US-4981863-A | ANTIANXIETY | MERRELL DOW PHARMACEUTICALS (US) | 1991-01-01 | — | — | US | claimed |
| US-4900743-A | TREATING MUSCLE SPASMS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-02-13 | — | — | US | claimed |
| CN-88100346-A | 3-aryl-5-alkylthio-4H-1, 2, 4-triazoles | — | 1988-11-02 | — | — | CN | claimed |
| EP-0276793-A2 | 3-Aryl-5-alkylthio-4H-1,2,4-triazoles | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-08-03 | — | — | EP | claimed |
| JP-4334373-A | — | — | None | — | — | JP | disclosed |
| US-7875643-B2 | (1S,5R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-3-azabicyclo[3.1.0]hexane; or(1S,5R)-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane; schizophrenia | GLAXO GROUP LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-7875643-B2 | (1S,5R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-3-azabicyclo[3.1.0]hexane; or(1S,5R)-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane; schizophrenia | GLAXO GROUP LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-7875643-B2 | (1S,5R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-3-azabicyclo[3.1.0]hexane; or(1S,5R)-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane; schizophrenia | GLAXO GROUP LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-7868177-B2 | Multi-cyclic compounds and method of use | AMGEN INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-0495226-A2 | 3-Aryl-5-alkylthio-4H-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-22 | — | — | EP | disclosed |
| US-4981863-A | ANTIANXIETY | MERRELL DOW PHARMACEUTICALS (US) | 1991-01-01 | — | — | US | disclosed |
| US-4900743-A | TREATING MUSCLE SPASMS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-02-13 | — | — | US | disclosed |
| CN-88100346-A | 3-aryl-5-alkylthio-4H-1, 2, 4-triazoles | — | 1988-11-02 | — | — | CN | disclosed |
| EP-0276793-A2 | 3-Aryl-5-alkylthio-4H-1,2,4-triazoles | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-08-03 | — | — | EP | disclosed |